Paul Tudor Jones Athira Pharma, Inc. Transaction History

Tudor Investment Corp Et Al

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $81,351 - $109,949	27,765 Added 66.1%	69,770 $207,000
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $115,093 - $564,127	42,005 New	42,005 $128,000
Q4 2020 Feb 16, 2021	SELL	$16.48 - $34.3 $1.55 Million - $3.22 Million	-94,003 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$16.02 - $18.46 $1.51 Million - $1.74 Million	94,003 New	94,003 $1.74 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $20.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.